Aripiprazole is an atypical antipsychotic indicated as oral formulations for the:
Treatment of schizophrenia in adults and adolescents (ages 13-17 years).
Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate in adults and pediatrics (ages 10-17 years).
Maintenance treatment of bipolar I disorder, both as monotherapy and as an adjunct to lithium or valproate in adults.
Adjunctive treatment of major depressive disorder (MDD) in adults.
Treatment of irritability associated with autistic disorder in pediatrics (ages 6-17 years).
